DR. MARGARET E. MCLAUGHLIN, M.D.
Medical Practice at Ellsworth Park, Cambridge, MA

License number
Massachusetts 203056
Category
Medical Practice
Type
Neuropathology
Address
Address
3 Ellsworth Park, Cambridge, MA 02139
Phone
(617) 871-4203

Professional information

Margaret Love Mclaughlin Photo 1

Margaret Love McLaughlin, Cambridge MA

Specialties:
Nephrologist
Address:
300 Mount Auburn St, Cambridge, MA 02138
Education:
Thomas Jefferson University, Jefferson Medical College - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Nephrology (Internal Medicine)


Margaret L Mclaughlin Photo 2

Dr. Margaret L Mclaughlin - MD (Doctor of Medicine)

Hospitals:
Franklin D Segall MD
300 Mount Auburn St STE 515, Cambridge 02138
Cambridge Health Alliance
1493 Cambridge St, Cambridge 02139
Mount Auburn Hospital
330 Mount Auburn St, Cambridge 02138
Franklin D Segall MD
300 Mount Auburn St STE 515, Cambridge 02138
Cambridge Health Alliance
1493 Cambridge St, Cambridge 02139
Mount Auburn Hospital
330 Mount Auburn St, Cambridge 02138
Education:
Medical Schools
Jefferson Medical College Of Thomas Jefferson University, Thomas Jefferson University
Graduated: 1980


Margaret E Mclaughlin Photo 3

Dr. Margaret E Mclaughlin, Cambridge MA - MD (Doctor of Medicine)

Specialties:
Neuropathology
Address:
3 Ellsworth Park, Cambridge 02139
(617) 871-4203 (Phone)
Languages:
English
Education:
Medical School
Harvard Medical School
Graduated: 1996
Brigham and Women's Hospital


Margaret Mclaughlin Photo 4

Steroid Modulators In The Treatment Of Peripheral Nerve Sheath Tumors

US Patent:
2005002, Feb 3, 2005
Filed:
Jul 24, 2003
Appl. No.:
10/626312
Inventors:
Margaret McLaughlin - Cambridge MA, US
Tyler Jacks - West Newton MA, US
International Classification:
A61K031/56
US Classification:
514169000, 514182000
Abstract:
The invention features methods for treating and preventing a peripheral nerve sheath tumor in a mammal such as a human. The methods involve administering to the mammal a compound that modulates the biological activity of a gonatropic steroid receptor, such as the progesterone receptor in an amount sufficient to inhibit the growth of the peripheral nerve sheath tumor. The mammal may be administered with the compound alone or in combination with a second therapeutic regimen. Also disclosed are screening methods that make use of gonatropic steroid receptors for the identification of novel therapeutics for PNSTs.